Research and experimental development on natural sciences and engineering
IMMUNOQUEST THERAPEUTICS AS
Revenue 2024
NOK 0
Operating profit
NOK −718,000
Equity
NOK −721,000
Incorporated
2023
Share capital
NOK 43,000
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 0 | |
| Total operating costs | 718k | |
| Operating profit (EBIT) | −718k | |
| Net financial items | −33k | |
| Profit for the year | −752k |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 438k | |
| of which current assets | 407k | |
| Equity | −721k | |
| Total liabilities | 1.2m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.